postibrutinib 1
outcomes 1
patients 3
mantle 3
cell 3
lymphoma 4
combination 1
bendamustine 1
bortezomib 2
rituximab 1
relapsedrefractory 1
indolent 1
nonhodgkin 2
inhibition 1
syk 1
fostamatinib 1
disodium 1
has 1
significant 1
clinical 1
activity 1
chronic 1
lymphocytic 1
leukemia 1
multicenter 1
phase 1
ii 1
study 1
relapsed 1
refractory 1
